Estelamari Rodriguez

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Astra Zeneca
    Topic:
    lung cancer
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    OncLive
    Topic:
    lung cancer
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Amgen
    Topic:
    lung cancer
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Janssen (Any division)
    Topic:
    lung cancer
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Genentech
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Research to Practice
    Topic:
    lung cancer
    Date added:
    08/13/2024
    Date updated:
    08/13/2024
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology